"Dr. Jagannath On Treatment Advances In Transplant-Ineligible Patients With Myeloma"
Sundar Jagannath, MD, director of the myeloma program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma. “Patients who are not eligible for transplant are often elderly and frail patients over the age of 75 or 80 with renal impairment and comorbidities. With immunotherapy and other novel therapies, physicians are able to safely give combination therapy to these patients,” said Dr. Jagannath. These approaches result in meaningful remissions. He added, “The second notable advance in this setting is the ability to look for minimal residual disease (MRD) in the bone marrow. Now, more patients are going into complete remission or stringent complete remission—both biochemical remissions—as well as demonstrating morphologically negative bone marrow.”
— Sundar Jagannath, MD, Professor, Medicine, Hematology, Medical Oncology, Director, Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai